Farallon Capital Management, L.L.C. and associated individuals filed an amended beneficial ownership statement with the SEC on November 12, 2026, reporting shared ownership of 14,247,000 shares of BridgeBio Pharma, Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate position: Farallon Capital Management, L.L.C. reported beneficial ownership of 14,247,000 shares of BridgeBio Pharma, Inc. common stock.
  • Ownership percentage: The 14,247,000 shares represent 7.3% of the class, according to the filing.
  • Shared power only: All reporting persons listed zero sole voting power and zero sole dispositive power; all 14,247,000 shares are held with shared voting and shared dispositive power.
  • Triggering event date: The filing identifies September 30, 2026 as the date of the event requiring this statement.
  • Amendment number: This is Amendment No. 2, indicating a prior version of this beneficial ownership statement was on file.
  • Multiple reporting persons: Thirteen individuals are listed as co-reporting persons alongside the investment adviser entity, each attributed the same 14,247,000 share total.
  • Security covered: The filing covers common stock with par value $0.001 per share, CUSIP 10806X102, issued by BridgeBio Pharma, Inc.

Farallon Capital and Co-Filers Report 7.3% Stake in BridgeBio Pharma

According to the filing, Farallon Capital Management, L.L.C., a Delaware-organized investment adviser, together with thirteen named individuals, reported a combined beneficial ownership position of 14,247,000 shares in BridgeBio Pharma, Inc. (NASDAQ:BBIO), a clinical-stage pharmaceutical company. The filing is styled as Amendment No. 2, covering a triggering event dated September 30, 2026, and was submitted to the SEC on November 12, 2026. Each reporting person is attributed the identical aggregate share count of 14,247,000, representing 7.3% of the outstanding class.

The filing discloses that none of the reporting persons hold any sole voting power or sole dispositive power over the shares. Instead, the entire position of 14,247,000 shares is reported under shared voting power and shared dispositive power for each of the reporting persons listed. Farallon Capital Management, L.L.C. is identified by type code "IA, OO," denoting an investment adviser, while the thirteen individual co-filers carry type codes "HC, IN," indicating holding company and individual classifications, as described in the filing.

The thirteen individuals named in the filing alongside the investment management entity are: Joshua J. Dapice, Philip D. Dreyfuss, Hannah E. Dunn, Varun N. Gehani, Nicolas Giauque, Avner A. Husen, David T. Kim, Michael G. Linn, Patrick (Cheng) Luo, Thomas G. Roberts Jr., Edric C. Saito, Daniel S. Short, and Andrew J. M. Spokes. BridgeBio Pharma, Inc. is focused on genetic disease drug development, and its common stock trades on NASDAQ under the ticker BBIO with a par value of $0.001 per share and CUSIP 10806X102.

What Was Disclosed

Farallon Capital Management, L.L.C. and thirteen associated individuals filed an amended beneficial ownership statement reporting 14,247,000 shares, equal to 7.3% of BridgeBio Pharma, Inc.'s common stock, with all power held on a shared basis as of September 30, 2026.